

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcement of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 October 2016 in relation to the research and development results of chimeric antigen receptor T (“**CAR-T**”) cell technology in immunotherapy for cancer cure by Nanjing Legend Biotechnology Co., Ltd.* 南京傳奇生物科技有限公司 (“**Nanjing Legend**”), a wholly-owned subsidiary of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to further announce that on 13 May 2017, Nanjing Legend was invited to present the results of the application of its proprietary CAR-T technology targeting multiple myeloma at the “Clinical Trials Spotlight Symposium” session at the 2017 annual meeting of The American Society of Gene & Cell Therapy (“**ASGCT**”). ASGCT is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new genetic and cellular therapies.

The clinical research and development yields promising results. As of December 2016, Nanjing Legend has applied its proprietary CAR-T technology to treat 19 relapsed or refractory multiple myeloma patients and followed up for four to 14 months. Among the treated patients, 14 consistently achieved diagnostic criteria of “stringent complete response” and four achieved “very good partial response” and were recently expected to achieve “complete response”. One patient did not proceed with the clinical trial for unexpected onset of other serious disease. None of the treated patients had serious adverse event or fatal events, with only two of them experienced transient grade ≥ 3 adverse event. The clinical research results showed that the CAR-T technology has the potential to bring curing solutions to multiple myeloma patients under a safe and effective treatment.

Multiple myeloma is a fatal cancer of bone marrow plasma cell affecting one to five per 100,000 individuals. As CAR-T cell therapy is recently demonstrating clinical efficacy and safety profile in treating certain kinds of leukemia and lymphoma, increasing attempts in developing CAR-T cell therapy to treat multiple myeloma have been made worldwide. The Group believes that its proprietary CAR-T cell technology has significant potential in clinical cancer therapeutics, the promising clinical research results further boost the Group's plan to capture the growth opportunities in the clinical research services market by continuing its research and development in more cancer immunotherapy and expand into the development and application of CAR-T cell therapy.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 14 May 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*